Invention Grant
- Patent Title: 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors
-
Application No.: US15817562Application Date: 2017-11-20
-
Publication No.: US10039755B2Publication Date: 2018-08-07
- Inventor: Stephen John Atkinson , Michael David Barker , Matthew Campbell , Hawa Diallo , Clement Douault , Neil Stuart Garton , John Liddle , Robert John Sheppard , Ann Louise Walker , Christopher Wellaway , David Matthew Wilson
- Applicant: Glaxo Group Limited
- Applicant Address: GB Brentford
- Assignee: Glaxo Group Limited
- Current Assignee: Glaxo Group Limited
- Current Assignee Address: GB Brentford
- Agency: Dechert LLP
- Agent Andrea L. C. Reid
- Main IPC: A61K31/4545
- IPC: A61K31/4545

Abstract:
Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
Public/Granted literature
- US20180161316A1 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS Public/Granted day:2018-06-14
Information query
IPC分类: